Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals, Inc. reports developments across a diversified pharmaceutical business built around Affordable Medicines, Specialty and AvKARE. Its updates commonly cover U.S. launches of complex generics, injectables, biosimilars and other affordable medicines, including respiratory inhalation and ophthalmic products, as well as branded specialty treatments in neurology and endocrinology.
News about AMRX also includes clinical and regulatory disclosures for products such as CREXONT for Parkinson’s disease, financial results, capital-structure updates, material agreements and governance matters. AvKARE-related updates center on distribution of pharmaceuticals and medical products to U.S. federal, retail and institutional customers.
Amneal Pharmaceuticals (Nasdaq: AMRX) announced positive topline results from a Phase 3 clinical trial for ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences. The study met its primary and secondary endpoints, demonstrating therapeutic equivalence and comparable safety to XOLAIR® in 400 patients with Chronic Idiopathic/Spontaneous Urticaria.
The trial evaluated doses of 150mg or 300mg administered subcutaneously every four weeks over 24 weeks. Amneal holds exclusive U.S. commercialization rights, with a Biologics License Application (BLA) planned for Q4 2025. The biosimilar targets the $3.9 billion U.S. omalizumab market and is part of Amneal's strategy to launch six biosimilars across eight product presentations by 2027.
Amneal Pharmaceuticals (NASDAQ: AMRX) has announced its participation in two major investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference on June 5 at 9:20 AM ET and participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 10 at 10:40 AM ET.
Co-CEO and President Chirag Patel and CFO Tasos Konidaris will represent Amneal at both events. Investors can access live webcasts through the company's investor relations website, with replay options available after the events.
Amneal Pharmaceuticals (NASDAQ: AMRX) has received FDA approval for Brekiya®, the first and only dihydroergotamine (DHE) autoinjector for acute treatment of migraine and cluster headaches in adults. The product will be available in H2 2025.
Brekiya represents a significant advancement as it allows patients to self-administer the same DHE medication used in hospitals through a convenient, ready-to-use autoinjector that requires no refrigeration, assembly, or priming. The device delivers one subcutaneous dose into the thigh and may provide sustained pain relief for up to 24-72 hours.
This innovation addresses a substantial market, with 39 million Americans suffering from migraines and up to 1 million affected by cluster headaches. Headaches represent the fourth most common reason for emergency department visits, accounting for 3% of all ER visits in the US.
Amneal Pharmaceuticals (NASDAQ: AMRX) and Apiject Systems have announced a strategic collaboration to expand domestic production of Apiject's Blow-Fill-Seal (BFS) injectable platform at Amneal's Brookhaven, NY facility. The partnership will create approximately 200 new jobs and enable production capacity of 250-300 million units annually, scalable to over 400 million units.
The collaboration integrates BFS manufacturing with precision injection molding of pen-style needle hubs, creating sterile, single-dose, prefilled injectors. This technology, partially developed through a $180 million investment from HHS, offers a more efficient alternative to traditional glass vials and syringes. The project will enhance Amneal's U.S. manufacturing capabilities for sterile drug dosage forms, including injectables, ophthalmics, and inhalation products.
Amneal Pharmaceuticals (Nasdaq: AMRX) has announced a significant $1.5 million donation to multiple patient assistance foundations supporting individuals with Parkinson's disease during Parkinson's Awareness Month.
The donation aims to help offset out-of-pocket costs, including copayments, coinsurance, and deductibles for FDA-approved Parkinson's medications. This initiative addresses the financial challenges faced by over 10 million people worldwide affected by this progressive disease.
Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty at Amneal, emphasized that access to medication shouldn't be a barrier for Parkinson's patients. The company's contribution focuses on breaking down financial obstacles and improving treatment accessibility to help patients live fuller, more empowered lives.
Amneal Pharmaceuticals (NASDAQ: AMRX) has scheduled the release of its first quarter 2025 financial results for Friday, May 2, 2025, before market open. The company will host an audio webcast at 8:30 a.m. ET on the same day.
Investors and interested parties can access the webcast through the company's Investor Relations website at https://investors.amneal.com. For those preferring a conference call, dial-in options are available at 1 (833) 470-1428 for U.S. participants, with international numbers also provided. The access code for the call is 170097.
Amneal Pharmaceuticals (AMRX) has announced new Phase 3 study data demonstrating significant improvements in sleep quality for Parkinson's disease patients using CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules.
The RISE-PD study analysis revealed that patients who converted from immediate release (IR) carbidopa/levodopa to CREXONT showed statistically significant improvements in Parkinson's Disease Sleep Scale-2 (PDSS-2) scores, with a mean difference of -2.35 (p0.0001). Patients experienced improvements across all PDSS-2 subdomains, including reduced disturbed sleep (-1.07), improved nighttime motor symptoms (-0.62), and PD symptoms at night (-0.65).A separate analysis showed that CREXONT treatment resulted in more patients waking up in an 'On' state compared to IR CD/LD patients. Amneal has initiated a Phase 4 trial, ELEVATE-PD, to evaluate real-world efficacy and safety. The most common adverse reactions with CREXONT were nausea and anxiety.
Amneal Pharmaceuticals (NASDAQ: AMRX) announced expanded insurance coverage for CREXONT®, its Parkinson's disease treatment, with three major insurers: Veterans Administration, UnitedHealthcare, and CVS Health. This expansion increases total U.S. coverage from 30% to over 50% of covered lives, achieved nine months ahead of their end-2025 target.
CREXONT, FDA-approved in August 2024, combines immediate-release granules with extended-release pellets, making it the longest-lasting oral carbidopa/levodopa formulation available. Clinical trials demonstrated 1.55 more hours of 'Good On' time per dose compared to immediate-release alternatives, representing a 70% increase in symptom control time.
The coverage rollout includes: VA's immediate national formulary addition (covering ~10% of U.S. PD patients), UnitedHealthcare's addition in Q2 2025, and CVS Health's inclusion as a 'preferred' product starting July 1, 2025.